Clinical trials
Papillary Thyroid Cancer clinical trials
Below are recruiting papillary thyroid cancer clinical trials, each written for real people, not researchers. We’re tracking 45 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05852223RecruitingPhase 2
Pembrolizumab for high-risk thyroid cancer that cannot be fully removed
This study tests pembrolizumab (an immune therapy) in people with high-risk thyroid cancer that is hard to treat with surgery alone. It looks at whether this drug can reduce persistent or recurrent cancer after your planned treatment.
Pavia, LombardyAges 18 years+ - NCT05604963Recruiting
Half or full thyroid surgery for low-risk thyroid cancer
This study looks at people with low-risk thyroid cancer who have already had (or are about to have) surgery, comparing half-thyroid removal versus full-thyroid removal. It may help doctors choose the safest and most effective surgery for your cancer type and risk level.
Crewe, CheshireAges 16 years+ - NCT04892303RecruitingPhase 1
Planning treatment using radiation plus radioactive iodine for thyroid cancer
This Phase 1 study tests how doctors plan a combination of two radiation approaches—external beam radiation and radioactive iodine—for thyroid cancer that is not fully responding to standard treatment. It may help people who still have iodine-avid tumor spots, but whose iodine uptake looks too low to work well with radioactive iodine alone.
Baltimore, MarylandAges 18–85 - NCT06959511RecruitingPhase 2
Zanzalintinib for advanced thyroid cancer before surgery
This trial tests a drug called zanzalintinib for people with advanced thyroid cancer that has spread nearby. The goal is to see if taking this pill before surgery can shrink the tumor and make it easier to remove.
Ann Arbor, MichiganAges 18 years+ - NCT07287748RecruitingPhase 1
Studying AF-001 for advanced thyroid cancer
This trial tests a new drug called AF-001 for people with thyroid cancer that has spread and can't be removed with surgery. It's for those who didn't benefit from or can't take standard treatments, or who haven't had radioactive iodine therapy yet.
KashiwaAges 18 years+ - NCT07054229Recruiting
Microwave ablation for low-risk thyroid microcancer
This study looks at whether microwave ablation, a minimally invasive treatment, works as well as surgery for small, low-risk thyroid cancers. It uses special ultrasound and genetic tests to help decide the best treatment.
Guangzhou, GuangdongAges 18–70 - NCT06725576Recruiting
Comparing microwave ablation vs. surgery for low-risk thyroid cancer
This study compares a less invasive procedure (microwave ablation) with traditional surgery for treating a small, low-risk papillary thyroid cancer. If you have a single, small tumor with certain low-risk gene changes, you might be able to avoid surgery and have a quicker recovery.
Guangzhou, GuangdongAges 18–70 - NCT06133374Recruiting
Genetic testing accuracy: needle biopsy vs. surgery
This study compares genetic testing results from a small needle biopsy to those from the surgically removed thyroid tissue. It aims to see if the biopsy alone can accurately predict the cancer's genetics, which could help guide treatment decisions.
Calgary, AlbertaAges 18 years+ - NCT06220656Recruiting
Thyroid nodule observation and biopsy study
This study looks at how doctors talk with patients who have a thyroid nodule that may need a biopsy. It aims to improve communication and help patients feel more involved in their care.
Lebanon, New HampshireAges 18 years+ - NCT07218315Recruiting
Electric Pulse Treatment for Small Thyroid Cancers
This trial is testing a new, non-surgical treatment that uses short electric pulses to destroy small papillary thyroid cancers. It may be an option for people with small tumors that haven't spread.
Sarasota, FloridaAges 18 years+ - NCT07440290RecruitingPhase 2/Phase 3
Dabrafenib and trametinib for BRAF V600 cancers
This trial tests two targeted drugs (dabrafenib and trametinib) for patients whose cancer has a specific change in the BRAF gene called V600. These drugs work together to block signals that help the cancer grow. The trial is for children, teenagers, and adults with many types of cancer, except for a few common ones that already have approved treatments.
BelfastAges 1 year+ - NCT06853925Recruiting
Online program for thyroid cancer symptom management
This study tests a web-based program to help people with thyroid cancer manage symptoms from radioactive iodine (RAI) treatment and improve their quality of life. It is for those who have had RAI within the past three years and are experiencing mild to moderate symptoms.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06359847RecruitingPhase 2
ST-1898 for advanced thyroid cancer that no longer responds to iodine therapy
This trial tests an experimental drug called ST-1898 for people with advanced thyroid cancer that has stopped responding to radioactive iodine treatment and has progressed after at least one targeted therapy. It aims to see if ST-1898 can shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06475989RecruitingPhase 3
Targeted therapy vs. chemotherapy for thyroid cancer
This trial compares a targeted therapy pill combination (dabrafenib and trametinib) with cabozantinib or chemotherapy for people with a specific type of advanced thyroid cancer (differentiated thyroid cancer) that has a BRAF V600E mutation. It aims to find which treatment works better after previous treatments have stopped working.
Anchorage, AlaskaAges 18 years+ - NCT06482086RecruitingPhase 2
Using tumor models to guide drug choice for advanced thyroid cancer
This trial tests whether growing your tumor cells in a lab (as organoids) can help doctors pick the best drugs for advanced thyroid cancer that is hard to remove surgically. It's for people with different thyroid cancer types who have tumors growing outside the thyroid or into nearby areas.
Chengdu, SichuanAges 18 years+ - NCT06440850RecruitingPhase 2
Targeted therapy for high-risk BRAF-mutated thyroid cancer
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
Duarte, CaliforniaAges 18 years+ - NCT06855680Recruiting
EMIRATES: Observing low-risk thyroid cancer without completion surgery
This study tests whether it is safe to monitor small, low-risk thyroid cancers (1–4 cm) instead of removing the remaining thyroid tissue after initial surgery. It may help you avoid a second operation and lifelong medication if your cancer is truly low-risk.
WiganAges 18 years+ - NCT04290663RecruitingPhase 3
Radioiodine decision after thyroid surgery for intermediate-risk cancer
This study compares two approaches after thyroid surgery: giving radioactive iodine right away versus deciding based on follow-up test results. It aims to see which approach better helps people with intermediate-risk differentiated thyroid cancer.
Pointe à Pitre, GuadeloupeAges 18 years+ - NCT02363595Recruiting
Genetic clues for how small thyroid cancers may grow
This study looks at gene changes to predict whether a small papillary thyroid cancer found on biopsy is likely to stay stable or grow over time. It may help doctors choose who can safely stay on watchful waiting.
New York, New YorkAges 18 years+ - NCT04981509RecruitingPhase 2
Check if 3 medicines help advanced kidney cancer
This Phase 2 trial tests whether combining bevacizumab, erlotinib, and atezolizumab can shrink or control advanced kidney cancer. It’s aimed at people with certain kidney-cancer subtypes (including HLRCC-related cases or papillary kidney cancer) and who have not had many prior targeted or immune treatments.
La Jolla, CaliforniaAges 12 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Birmingham, AlabamaAges 18 years+
Hear when a new Papillary Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for papillary thyroid cancer?
- Yes. Clin2 currently lists 45 recruiting papillary thyroid cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a papillary thyroid cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a papillary thyroid cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.